Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade

Circulation

Volumn 95, Issue 4, 1997, Pages 860-867

  Coller, Barry S ^a   Lang, Daniel ^a   Scudder, Lesley E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

fibrinogen; glycoproteins; platelets; receptors

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BLOOD ANALYSIS; CHIMERA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE HOMOLOGY; THROMBOCYTE FUNCTION;

EID: 0031058513     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.4.860     Document Type: Article

References (30)

1. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
3. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
4. Topol EJ, Califf RM, Weismann HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
5. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman H, Berger H. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
6. Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis. 1992;3:1016-1029.
7. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980;55:169-178.
8. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
9. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Invest. 1985;76:101-108.
10. Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, Prestwich GD. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem. 1993;268:20741-20743.
11. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman H, Ghrayeb J. Humanizing the constant region of the 7E3 murine monoclonal Fab antibody fragment reduces the immunogenicity of the variable region in humans. Mol Immunol. 1995;32:1271-1281.
12. Beer JH, Springer KT, Coller BS. Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet GPIIb/IIIa receptor. Blood. 1992;79:117-128.
13. Foster MR, Pike NB, Hornby EJ, Eldred CD, Ross BC, Lumley P. GR144053, a potent and specific non-peptide fibrinogen receptor antagonist on human platelets in vitro. Thromb Haemost. 1993;69:64. Abstract.
14. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 1991;77:75-83.
15. 2 fragments of a monoclonal antibody. Blood. 1985;66:1456-1459.
16. Channing-Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Haemost. 1990;16:1-20.
17. Coller BS. Platelet aggregation by ADP, collagen and ristocetin: a critical review of methodology and analysis. In: Schmidt RM, ed. CRC Handbook Series in Clinical Laboratory Science, Section 1: Hematology. Boca Raton, Fla: CRC Press, Inc; 1979:381.
18. Mascelli MA, Lance E, Mack S, Weisman H, Schaible T, Jordan R. Rapid assessment of platelet inhibition using a modified whole blood aggregometer (Aggrestat) in PTCA patients receiving ReoPro. J Am Coll Cardiol. 1996;27:361A. Abstract.
19. Greilich PE, Alving BM, O'Neill KL, Chang AS, Reid TJ. Modified thromboelastography: a rapid, simple method for monitoring c7E3 Fab in heparinized patients. Blood. 1995;86:545a. Abstract.
20. Kundu S, Heilmann E, Sio R, Garcia C, Ostgaard R. Characterization of the platelet function analyzer, PFA-100™. Thromb Haemost. 1995;73:1061. Abstract.
21. Breddin HK, Breddin H, Kirchmaier CM, Keppler S. Methods to monitor the effects of glycoprotein IIb/IIIa inhibitors and their interactions with other antithrombotic agents. Thromb Haemost. 1995;73:1446. Abstract.
22. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors. Circulation. 1989;80:1766-1774.
23. Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis. 1993;4:729-737.
24. Anderson DR, Zayed E, Embree J, Theroux P, Steiner B. Flow cytometry as a quantitative measure of the antiplatelet activity of a glycoprotein IIB/IIIA inhibitor. Blood. 1995;86:893a. Abstract.
25. Murphy N, Jennings L, Pratico D, Doyle C, Fitzgerald DJ. Functional relevance of LIBS expression in the response to platelet glycoprotein antagonists in vivo. Thromb Haemost. 1995;73:1314. Abstract.
26. Heath TL, Wall CD, Jennings LK. A GP IIIa ligand-induced binding site antibody detects multiple GP IIb-IIIa conformations, and its binding is modulated by various ligands. Ann N Y Acad Sci. 1994;714:300-302.
27. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64-73.
28. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ, for the GUSTO-1 Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation. 1996;93:870-878.
29. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383-1395.
30. Wagner CL, Cunningham MR, Wyand MS, Weisman HF, Coller BS, Jordan RE. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys. Thromb Haemost. 1995;73:1313. Abstract.